Catapult Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering its Humanized Anti-CCR7 Antibody CAP-100
Lelystad, The Netherlands, 6 May 2020 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, today announced receiving Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for the U.S. patent application covering composition of matter for its family of humanized anti-CCR7 antibodies. When issued, the U.S. patent will not expire until at least 2035.
A Notice of Allowance announces that the patent application is considered ready for approval. However, the process is still ongoing, and it is currently not possible to predict when a patent will be granted.
“This Notice of Allowance from the USPTO is a major development, representing one of the most significant patent applications ever allowed to our company,” stated Wim Mol, Chief Executive Officer of Catapult. “This patent, in conjunction with our existing patent on the use of anti-CCR7 antibodies in cancer, will be a core component of the commercial protection strategy for CAP-100 in the U.S., the world’s largest pharmaceutical market. It will both enhance and expand substantially our U.S. market exclusivity for CAP-100 and strengthen us in our discussions with future partners. We are continuing to pursue additional patents for CAP-100, in the U.S. and other major pharmaceutical markets, to further fortify our global patent portfolio for this promising drug candidate.”